Join Us at the 2021

Canadian Breast Cancer Digital Symposium

We are showcasing MammaPrint® and BluePrint® genomic tests for comprehensive profiling of early-stage breast cancer.

Register for the meeting and visit our virtual booth

Click Here to View The Digital Symposium

Dr. Conter’s Symposium Presentation Information:

Integrating MammaPrint and BluePrint Molecular Subtyping into Treatment Planning for Patients with Early Stage Breast Cancer

Join Us Friday, June 18, 2021 at 9:00 AM – 9:30 AM

Henry J. Conter, BESc, MD, MSF, MSc
Professor of Medicine, University of Western Ontario, Schulich School of Medicine & Dentistry
Medical Oncologist, William Osler Health System

This symposium will explore real-world utilization of the 70-gene and 80-gene breast cancer genomic tests at a Canadian breast center and how integrating genomics in both pre-operative and post-operative decisions can help optimize the treatment management for early-stage breast cancer patients.

Learning Objectives:

  • Review MammaPrint and BluePrint’s clinical utility for patients with early stage breast cancer
  • Discuss the impact of knowing the functional molecular subtype in the neoadjuvant or adjuvant setting
  • Case based review and real world utilization impact of MammaPrint + BluePrint genomic testing

Henry J. Conter, BESc, MD, MSF, MSc

Dr. Henry Conter is a practicing medical oncologist/hematologist at William Osler Health System and an adjunct professor at the University of Western Ontario, Schulich School of Medicine & Dentistry. Dr. Conter is also a Strategic Health Care Partner at Hoffmann-La Roche. Prior to joining Roche, Dr. Conter has a track record for innovation and excellence in leadership as Medical Director of the Cancer Health System, and Executive Medical Director of Quality, Patient Safety, and Health System integration at Osler. He served as a voting member on the Ontario Steering Committee for Cancer Drugs and a member of the pan-Canadian Oncology Drug Review (pCODR) Expert Review Panel and CADTHs national Pharmacare Advisory Panel as the oncology representative. Previously he served on pCODR’s Economic Guidance Panels and Clinical Guidance Panels.

RSVP today

Trusted by leading physicians and institutions around the world

Our Tests

At the genomic level, physicians can examine the activity of specific genes inside a tumor – how they interact to drive the behavior of a tumor.

View More Information
Genomic Testing Cell Photo

Landmark Studies

Data on the validation and utility of MammaPrint and BluePrint for patients with early stage breast cancer.

View More Information
Two women reading about genomic breast cancer results

Latest News

The most recent data and news from Agendia to keep you up-to-date on how our tests can support you and your patients.

Read the article

For the US, Puerto Rico, Canada and South America

Agendia Inc. USA
22 Morgan
Irvine, CA 92618
(888) 321-2732


For outside the Americas

Agendia NV
Radarweg 60
1043 NT Amsterdam
The Netherlands
+31 (0)20 462 1510